Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Immgolis, Immgolis Intri. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Golimumab-Sldi (sold as Immgolis, Immgolis Intri), first approved May 15, 2026, with 0 new uses approved and 0 published complete response letters.
First approved in Japan 178 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
SimponiDrugs with a new additional indication and a new dosage, in a new additional dosage form for improvement and maintenance of moderate to severe ulcerative… · Janssen Pharmaceutical K.K. · Mar 30, 2017
Simponi, new ingredientA drug with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who… · Janssen Pharmaceutical K.K. · Jul 1, 2011
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA